Quick comparison
| Peptide | Class | Evidence | Status |
|---|---|---|---|
| PT-141 (Bremelanotide) | Cyclic heptapeptide (melanocortin receptor agonist) | Moderate | FDA-approved (Vyleesi) for premenopausal women with HSDD; off-label elsewhere |
| Kisspeptin | Neuropeptide (HPG axis regulator) | Emerging | Not FDA-approved for sexual dysfunction; FDA flags as category 2 bulk substance risk |
| Melanotan II | Cyclic heptapeptide (melanocortin agonist) | Limited | Not FDA-approved; flagged as high-risk category 2 bulk substance |
| Oxytocin | Nonapeptide hormone | Limited | Not FDA-approved for sexual dysfunction; marketed off-label |
The ranking
PT-141 (Bremelanotide)
PT-141, also known as bremelanotide and sold under the brand name Vyleesi, is a synthetic peptide that activates melanocortin receptors (MC3/MC4) in the brain and hypothalamus to drive sexual desire and arousal, rather than acting on blood flow like PDE5 inhibitors such as Viagra or Cialis.
It holds the top spot in this category because it is the only peptide with FDA approval, backed by Phase 2 and Phase 3 randomized controlled human trials in women with HSDD, and it is the most consistently documented compound across clinical and commercial sources alike.
Human observational and trial data also show it can induce erections in men without visual sexual stimulation, supporting a central rather than purely vascular mechanism, which is part of why it sees common off-label use in men despite approval being limited to premenopausal women.
Trial data show statistically significant but mild improvements in desire, with placebo groups also showing meaningful gains, so expectations should stay measured.
Strengths
- Only peptide in this category with FDA approval and Phase 2/3 RCT evidence in humans
- Mechanism (central melanocortin activation) is distinct from and well-differentiated against PDE5 inhibitors
- Administered on-demand rather than daily, with a defined dosing ceiling in prescribing information
Limitations
- Common side effects include nausea, flushing, and headache; rare hyperpigmentation reported with overuse
- Not indicated for HSDD caused by relationship issues, other medical/psychiatric conditions, or medication side effects
- Gray-market/compounded versions carry purity and dosage risks distinct from FDA-regulated Vyleesi
- Best for
- Low sexual desire (HSDD) unresponsive to other causes
- Evidence
- Moderate
- Status
- FDA-approved (Vyleesi) for premenopausal women with HSDD; off-label elsewhere
Kisspeptin
Kisspeptin is a naturally occurring neuropeptide that stimulates GnRH neurons in the hypothalamus, upstream of the pathway that raises LH and testosterone.
A randomized, placebo-controlled crossover human trial in men with hypoactive sexual desire disorder found kisspeptin enhanced brain processing related to sexual stimuli and reduced sexual aversion, supporting a role in motivational or “priming” signaling rather than direct performance effects.
The same body of research found no sustained improvement in erectile function or long-term libido, so it ranks below PT-141 as a more investigational option.
The FDA has separately classified kisspeptin as a category 2 bulk substance, indicating notable safety concerns in compounded forms.
Strengths
- Human RCT (crossover design) shows measurable effects on sexual brain processing in men with HSDD
- Reduced sexual aversion observed in controlled trial conditions
- Mechanistically distinct: acts upstream on HPG axis rather than mimicking existing drug classes
Limitations
- No sustained improvement in erectile function or long-term libido shown in trials
- FDA has flagged it as a category 2 bulk substance due to compounding safety concerns
- Evidence base is limited to a single small crossover study, not broad clinical use
- Best for
- Men with HSDD seeking research-backed neuroendocrine priming, not performance fix
- Evidence
- Emerging
- Status
- Not FDA-approved for sexual dysfunction; FDA flags as category 2 bulk substance risk
Melanotan II
Melanotan II is a synthetic melanocortin agonist that acts on MC3/MC4 receptors in the same central pathway as PT-141, producing pro-erectile effects through brain signaling rather than direct vascular action.
Its clinical development was abandoned after human trials revealed nausea, flushing, yawning, blood pressure changes, and a risk of spontaneous prolonged erections (priapism). Despite this, it continues to circulate through unregulated online sellers. The FDA’s updated 2023/2025 statement classifies melanotan II as a “category 2 bulk substance,” signaling significant safety concerns for compounding.
Strengths
- Shares a plausible pro-erectile mechanism with PT-141 (MC3/MC4 receptor activation)
- Early human trial data exists, unlike many gray-market compounds
Limitations
- Development was discontinued due to adverse effects including priapism risk
- Not FDA-approved for any indication and flagged as high-risk by the FDA
- Products sold online are unregulated, with no verified purity or dosage standards
- Best for
- Not recommended; historical comparator to PT-141's mechanism
- Evidence
- Limited
- Status
- Not FDA-approved; flagged as high-risk category 2 bulk substance
Oxytocin
Oxytocin is a nonapeptide often called the “bonding hormone,” promoted by wellness and functional medicine clinics as a way to enhance arousal, orgasm, and intimacy.
However, controlled human trials tell a different story: a large randomized controlled trial in women found no improvement in sexual function versus placebo, and a study of 29 heterosexual couples found intranasal oxytocin did not change arousal or penile erection, though men reported greater postcoital satisfaction.
This creates a direct conflict between commercial marketing claims and the clinical evidence base. Given the strength of the negative RCT data, oxytocin ranks lower than peptides with clearer or more consistent human evidence.
Strengths
- Some men reported greater postcoital satisfaction in a small couples study (human RCT)
- Widely available and heavily promoted for intimacy/bonding use
Limitations
- Large RCT in women showed no improvement in sexual function versus placebo (human trial)
- Couples study found no change in arousal or erection (human trial)
- Commercial promotion outpaces the actual controlled trial evidence
- Best for
- Curiosity about bonding/intimacy, not a validated arousal fix
- Evidence
- Limited
- Status
- Not FDA-approved for sexual dysfunction; marketed off-label
How we picked
Ranking was based on strength of human clinical evidence for sexual health specifically, including RCT data where available, mechanism plausibility, documented adverse effects, and current regulatory status. This ranking is not an endorsement of use.
Only PT-141 (as Vyleesi) is FDA-approved, and only for hypoactive sexual desire disorder in premenopausal women; every other use discussed here, including off-label use in men, is unapproved.
Important safety note
Outside of Vyleesi's approved indication, these compounds are largely sold as unregulated, research-use-only, or gray-market products with inconsistent purity and dosing. Human safety data is limited or mixed for kisspeptin, melanotan II, and oxytocin in a sexual health context, and melanotan II carries a known priapism risk. Anyone considering any of these should talk to a qualified clinician first; nothing here is dosing guidance.
Frequently asked questions
Is PT-141 basically a peptide version of Viagra?
No. Viagra works on blood flow through nitric oxide pathways, while PT-141 acts on melanocortin receptors in the brain to affect desire and arousal. They are not interchangeable and work through entirely different mechanisms.
Which of these peptides is actually FDA-approved?
Only PT-141, under the brand name Vyleesi, and only for hypoactive sexual desire disorder in premenopausal women. Kisspeptin, melanotan II, and oxytocin are not FDA-approved for any sexual health use.
Does oxytocin really help with libido or arousal?
Evidence is conflicted. Commercial wellness sources promote it heavily, but controlled human trials, including an RCT in women and a couples study, found no improvement in sexual function or erection compared to placebo.
Is melanotan II safe to use for sexual enhancement?
No, its development was abandoned due to adverse effects including nausea, flushing, and prolonged erections with priapism risk. The FDA has flagged it as a high-risk bulk substance despite it still circulating online.
What does kisspeptin actually do for sexual function?
RCT data shows it can shift brain processing around sexual cues and reduce sexual aversion in men with HSDD, but it hasn't shown sustained improvement in erectile function or long-term libido.
Can men legally get PT-141 prescribed?
Providers can prescribe it off-label for men since it's an approved drug, but this use falls outside its FDA indication and typically isn't covered by insurance. Off-label prescribing is legal but discretionary.
Of these four, which has the strongest safety and evidence profile?
PT-141 has the most human clinical data and the only FDA approval among the four, making it the most established option, though even its trial results show modest effect sizes and notable side effects.